Table 2.
Outcomes for BP-CCBs versus amlodipine, showing percentage with each diagnosis during the exposure period, and the risk ratio. A: patients with no prior neuropsychiatric diagnosis. B: patients with a prior neuropsychiatric diagnosis.
| A: no prior neuropsychiatric diagnosis | B: with prior neuropsychiatric diagnosis | |||||
|---|---|---|---|---|---|---|
| BP-CCB (%) | Amlodipine (%) | Risk ratio (95% CI) | BP-CCB (%) | Amlodipine (%) | Risk ratio (95% CI) | |
| Psychotic disorder | 0.4 | 0.5 | 0.76 (0.63–0.93) | 2.5 | 3.0 | 0.83 (0.74–0.94) |
| Schizophrenia | 0.1 | 0.2 | 0.64 (0.45–0.91) | 1.0 | 1.3 | 0.73 (0.60–0.89) |
| Affective disorder | 6.3 | 7.3 | 0.86 (0.82–0.90) | 32.6 | 33.5 | 0.97 (0.94–1.00) |
| Bipolar disorder | 0.4 | 0.5 | 0.82 (0.68–1.00) | 3.7 | 4.2 | 0.88 (0.80–0.98) |
| Major depressive disorder | 5.6 | 6.6 | 0.85 (0.81–0.90) | 29.0 | 29.7 | 0.98 (0.95–1.01) |
| Anxiety disorder | 7.1 | 8.2 | 0.86 (0.83–0.90) | 31.0 | 32.6 | 0.95 (0.92–0.98) |
| Sleep disorder | 8.7 | 9.9 | 0.88 (0.84–0.91) | 31.1 | 31.6 | 0.98 (0.95–1.01) |
| Substance use disorder | 5.0 | 6.2 | 0.81 (0.76–0.85) | 23.2 | 24.7 | 0.94 (0.91–0.98) |
| Delirium | 0.9 | 1.3 | 0.72 (0.63–0.81) | 3.2 | 3.4 | 0.95 (0.85–1.06) |
| Dementia | 1.0 | 1.2 | 0.82 (0.72–0.93) | 3.2 | 3.3 | 0.98 (0.87–1.10) |
| Movement disorder | 1.2 | 1.4 | 0.83 (0.74–0.92) | 6.3 | 6.2 | 1.02 (0.94–1.11) |
| Any of the above | 21.3 | 24.1 | 0.88 (0.86–0.90) | 71..6 | 72.6 | 0.99 (0.97–0.99) |
| Negative control outcomesa | 0.94 (0.87–1.02) | 0.92 (0.87–0.97) | ||||
Risk ratios in bold have 95% confidence intervals not including 1.
aMean of 12 negative control outcomes. Full details in Supplementary Table 6A.